Visualization of gland structure makes detection and management of MGD straightforward. MGD can be diagnosed and managed by measuring function and visualizing structure. The TearScience® Solution enables you to identify, diagnose and treat MGD without all the dry eye complexity.
There are an estimated 300 million dry eye sufferers worldwide. In the U.S. alone, patients spend $3.8 billion per year on symptom relief of this chronic and progressive dysfunction. Those with moderate to severe dry eye experience great discomfort and seek new approaches from traditional, palliative therapies, which temporarily relieve symptoms without addressing the root cause.
The TearScience® Solution for MGD addresses the primary cause of evaporative dry eye. Consisting of the SPEED™ questionnaire, LipiView®II with Dynamic Meibomian Imaging™ (DMI™), Korb MGE™, and LipiFlow®, the TearScience® Solution for MGD addresses MGD with effectiveness and confidence. In addition to treating moderate to advanced stages of MGD, early intervention is possible in pre-symptomatic MGD patients, with the objective to improve gland function and intervene before irreversible damage occurs.